Douglas Brand

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 536 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 303 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy

Angela Pathmanathan, H. McNair, Maria A. Schmidt et al. · British Journal of Radiology · 2019 · 73 citations · Full text

Medicine, Radiation Oncology, Radiology +16

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial

Douglas Brand, Sarah C. Brüningk, Anna Wilkins et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 52 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation

Anna Wilkins, Olivia Naismith, Douglas Brand et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 51 citations · Full text

Medicine, Oncology, Radiation Oncology +17